GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » EPS (Diluted)

Bioasis Technologies (FRA:107) EPS (Diluted) : €-0.02 (TTM As of Nov. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies EPS (Diluted)?

Bioasis Technologies's Earnings per Share (Diluted) for the three months ended in Nov. 2022 was €-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Nov. 2022 was €-0.02.

Bioasis Technologies's EPS (Basic) for the three months ended in Nov. 2022 was €-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Nov. 2022 was €-0.02.

Bioasis Technologies's EPS without NRI for the three months ended in Nov. 2022 was €-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Nov. 2022 was €-0.04.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Bioasis Technologies EPS (Diluted) Historical Data

The historical data trend for Bioasis Technologies's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies EPS (Diluted) Chart

Bioasis Technologies Annual Data
Trend Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19 Feb20 Feb21 Feb22
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.06 -0.04 -0.05 0.01 -0.03

Bioasis Technologies Quarterly Data
Feb18 May18 Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 - -0.01 -0.01

Competitive Comparison of Bioasis Technologies's EPS (Diluted)

For the Biotechnology subindustry, Bioasis Technologies's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioasis Technologies's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's PE Ratio distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's PE Ratio falls into.



Bioasis Technologies EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Bioasis Technologies's Diluted EPS for the fiscal year that ended in Feb. 2022 is calculated as

Diluted EPS (A: Feb. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-2.052-0)/72.167
=-0.03

Bioasis Technologies's Diluted EPS for the quarter that ended in Nov. 2022 is calculated as

Diluted EPS (Q: Nov. 2022 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-0.719-0)/78.213
=-0.01

EPS (Diluted) for the trailing twelve months (TTM) ended in Nov. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioasis Technologies  (FRA:107) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Bioasis Technologies EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioasis Technologies (FRA:107) Business Description

Traded in Other Exchanges
N/A
Address
157 Church Street, 19th Floor, New Haven, CT, USA, 06510
Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (FRA:107) Headlines

No Headlines